Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

AngioDynamics, Inc. (ANGO) — this company's answers

NO on the Q1 2024 call 2023-10-04 B
The model's full reasoning — Q1 2024 call → NO我们根据要求分析。需要判断是否存在一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明确反驳了该疑虑。 从电话会议中,我们看到管理层多次提到公司转型、Med Tech增长、NanoKnife、Auryon、机械血栓切除等。分析师的问题包括:NanoKnife增长、机械血栓切除稳定性、Auryon安装基数、Med Tech毛利率、APEX研究、资本配置和股票回购。 一个明显的疑虑可能是:公司能否实现盈利?或者Med Device业务下滑?或者现金消耗?管理层提到“我们预计在FY25末实现正现金流”,并且“Q1是现金使用最高的季度”。分析师没有直接问“你们什么时候盈利”,但管理层在回答中提到了调整后每股亏损和现金。 另一个可能的疑虑:机械血栓切除业务(AngioVac和AlphaVac)是否在衰退?管理层承认AngioVac同比下降但环比增长,AlphaVac增长缓慢,但强调临床反馈和即将到来的适应症。 更明显的疑虑可能是:公司能否从亏损转向盈利?或者Med Tech增长能否持续?但电话会议中,管理层多次强调“我们相信”、“我们预期”,而分析师的问题更多是关于具体业务。 再仔细看:分析师Jayson Bedford问“机械血栓切除,你似乎稳定了AngioVac。AlphaVac似乎仍停留在第一年。你能说明为什么AlphaVac增长应该改善吗?”这暗示了对AlphaVac的疑虑。管理层回答:完成APEX PE研究、设计改进等,但这些都是未来计划,不是本季度已发生的事实。 另一个疑虑:关于现金消耗。管理层提到“我们预计年底现金余额在6500万-7000万美元”,并且“Q1是现金使用最高的季度”。分析师没有直接问,但管理层主动提及。 还有关于Med Device业务:管理层说“Med Device业务提供了盈利和现金基础”,但增长只有2.3%,主要靠Ports和Solero。 最明显的公司特定疑虑可能是:公司能否实现盈利?因为公司持续亏损,调整后每股亏损-0.13美元。但管理层在回答中提到了“我们相信”、“我们预期”,没有提供本季度已经发生的具体证据来反驳亏损。 另一个疑虑:关于NanoKnife的可持续性?但NanoKnife增长强劲,这是本季度实际发生的。 再读一遍问题:要求“一个明确的疑虑”和“本季度的实际证据反驳它”。我认为最合适的疑虑是:机械血栓切除业务(特别是AlphaVac)能否成功?因为分析师明确提出了这个问题,管理层承认AngioVac下降但环比改善,AlphaVac增长缓慢,但管理层用未来计划(APEX研究、设计改进)来回应,而不是本季度已发生的实际证据。所以这不符合“本季度实际证据反驳”的条件。 另一个疑虑:关于现金消耗和融资能力?管理层说“我们有足够的现金”,但这是基于预测,不是本季度事实。 或许疑虑是:公司能否从亏损转向盈利?但管理层没有提供本季度盈利改善的具体证据,只是说“符合预期”。 再考虑:分析师John Young问“Med Tech毛利率,你指导65%上限,但感觉保守”,这暗示了对毛利率的疑虑,但管理层解释了原因,没有具体反驳。 我认为最符合的是:关于机械血栓切除的疑虑,但证据不足。 另一个可能:关于Auryon的安装基数?分析师问“增长是程序驱动还是资本销售?”管理层回答“净新安装约10%”,但强调利用率提升。这算实际证据吗?但这不是一个明确的疑虑。 再读一遍电话会议开头:管理层说“我们看到了改进”,但具体是什么? 也许疑虑是:公司能否实现正现金流?管理层说“我们预计FY25末正现金流”,但这是未来。 我倾向于认为,电话会议中没有一个明确的、被反复提及的、公司特定的疑虑,并且本季度实际证据反驳它。分析师的问题更多是询问业务细节,而不是表达怀疑。 但有一个点:管理层在回答Jayson关于机械血栓切除时,承认AngioVac下降但环比改善,并说“我们相信我们正在采取的措施正在获得积极牵引”,但这是信心,不是事实。 再考虑:关于NanoKnife,分析师问“增长美国与国际”,管理层给出了具体数字,这是实际证据,但疑虑是什么?没有疑虑。 也许疑虑是:公司能否维持增长?但增长是事实。 我认为最接近的是:关于公司能否实现盈利的疑虑,但管理层没有用本季度事实反驳,只是说“符合预期”。 因此,我判断没有明确的、被本季度证据反驳的疑虑。所以答案应为NO。 但再仔细看:管理层提到“我们相信我们正在采取的措施正在获得积极牵引”针对AngioVac,但AngioVac环比增长是事实,这算反驳吗?但疑虑是“AngioVac下降”,而环比增长是反驳,但同比下降仍然存在。而且管理层没有明确说“疑虑”,只是分析师问。 或许疑虑是“机械血栓切除业务能否增长?”但本季度AngioVac环比增长,AlphaVac有1.8百万收入,但整体下降5.8%。所以证据并不完全反驳。 我认为没有明确的、被反驳的疑虑。因此答案NO。

← Back to the full ANGO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.